SRT-2104
SRT-2104 is an experimental drug that was studied by Sirtris Pharmaceuticals as a small-molecule activator of the sirtuin subtype SIRT1. The compound progressed to Phase II human trials for Type [II diabetes] before development was discontinued, however it continues to be widely used in animal research into the functions of SIRT1.